Intelligence · Clinical Pipeline
Acadia Pharmaceuticals Pipeline
All ClinicalTrials.gov programs at Acadia Pharmaceuticals — phase, modality, and trial IDs.
- Programs
- 11
Quick answer
Acadia Pharmaceuticals has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
ACP-204
Acadia Pharmaceuticals B.V.
Alzheimer's Disease Psychosis
2 trials -
ACP-204
Acadia Pharmaceuticals B.V.
Lewy Body Dementia Psychosis
2 trials -
Carbetocin
Acadia Pharmaceuticals B.V.
Hyperphagia in Prader-Willi Syndrome
2 trials -
Pimavanserin
Acadia Pharmaceuticals B.V.
Schizophrenia
4 trials -
Pimavanserin
Acadia Pharmaceuticals B.V.
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
2 trials -
Pimavanserin
Acadia Pharmaceuticals B.V.
Adjunctive Treatment of Major Depressive Disorder
3 trials -
Pimavanserin
Acadia Pharmaceuticals B.V.
Irritability Associated With Autism Spectrum Disorder
2 trials -
Pimavanserin tartrate (ACP-103)
Acadia Pharmaceuticals B.V.
Parkinson's Disease Psychosis
4 trials -
Placebo
Acadia Pharmaceuticals B.V.
Dementia-related Psychosis
1 trial -
Trofinetide
Acadia Pharmaceuticals B.V.
Rett Syndrome
4 trials -
pimavanserin tartrate
Acadia Pharmaceuticals B.V.
Parkinson's Disease Psychosis
1 trial
Frequently asked questions
How many pipeline programs does Acadia Pharmaceuticals have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs